Friday, 15 Feb 2019

You are here

Recurrent Uveitis Increases the Risk of Ankylosing Spondylitis

Arthritis Research and Therapy reports on the epidemiologic association between recurrent anterior uveitis and ankylosing spondylitis (AS) noting that as the number of uveitis episodes increases, so does the incidence of AS.

Uveitis is the most common extra-articular manifestation of AS, occurring in up to 40% of AS patients. As such AS-related anterior uveitis may first present to the ophthalmologist, not by a rheumatologist.  These investigators asked the question - how oftent does recurrent anterior uveitis result in subsequent AS. 

A national cohort of10,483 patients with new-onset uveitis (seen between 2004 -2013) was compared to 52415 matched control subjects (never had uveitis).

After the first uveitis episode, the AS risk was 7 fold higher (incidence rate ratio = 7.4 compared to normal controls).

After the the second uveitis episode, the IRR further increased to 17.71.  High rates of AS were seen in both male and female patients with recurrent uveitis (IRR 284.1 and 268.7 per 100,000 person-years, respectively.

As disease controls, patients with RA or herniatiated vertebral discs did not show a correlation with the occurrence or recurrence of uveitis.

The risk of subsequent AS increased with the number of episodes of anterior uveitis. 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

SEAM-PsA Study - Does Monotherapy MTX Win Despite Losing to Etanercept in Psoriatic Arthritis?

The SEAM-PsA study examined the efficacy of methotrexate monotherapy, etanercept monotherapy or the combination of MTX and ETN in psoriatic arthritis patients, and found that ETN monotherapy was equivalent to combination therapy - and that both were superior to MTX alone in clinical (ACR and MDA) and radiographic responses.

Biologics in Psoriasis Tied to Better Heart Health

Biologic therapy for severe psoriasis was associated with better plaque morphology and less non-calcified coronary plaque, according to a prospective, observational study.

Low IBD Risk with Secukinumab

The interleukin-23 (IL-23)/IL-17 axis plays an important role in inflammation and infection. Some of these chronic immune-mediated inflammatory disorders include PsO, PsA, AS, and IBD. Patients with PsO, PsA, and AS have up to a four-fold risk of developing IBD versus the general population. One study also supported the role for gut inflammation in spondyloarthropathy.

Ixekizumab and Complete Resolution of Enthesitis and Dactylitis

IL-17 inhibitors have proven to be effective in psoriatic arthritis. Analyses of ixekizumab-treated PsA patients with enthesitis or dactylitis shows this approach to yield significant improvements in enthesitis and dactylitis.

Obesity Needs to be Treated in Psoriatic Arthritis

Obese patients with psoriatic arthritis (PsA) who followed a short-term, very low-energy diet showed improvements in multiple aspects of disease activity, a prospective study found.

Over a period of 6 months, patients on the restrictive diet (640 kcal/day) lost a median of 18.7 kg (41.2 lbs), which represented 18.6% of their weight, according to Eva Klingberg, MD, PhD, of the University of Gothenburg in Sweden, and colleagues.